Zobrazeno 51 - 60
of 6 058
pro vyhledávání: ''
Autor:
Jie Xiang, Jian Li, Chengqiang Li, Yuyan Zheng, Shengguang Zhao, Hecheng Li, Kai Chen, Yichao Han, Zenghui Cheng, Yuquan Wu, Xiaoyan Chen, Toni Lerut, Xi-Jia Feng, Weixiang Qi
Publikováno v:
European Journal of Cancer. 144:232-241
Background To investigate the safety and activity of preoperative pembrolizumab combined with chemoradiotherapy for resectable oesophageal squamous cell carcinoma (ESCC) ( ClinicalTrials.gov number, NCT03792347). Methods Twenty resectable ESCC patien
Publikováno v:
Cancer Medicine, Vol 10, Iss 3, Pp 914-922 (2021)
Cancer Medicine
Cancer Medicine
The previous retrospective study suggested that dosing vitamin K may enhance the anticancer action of sorafenib against hepatocellular carcinoma. To confirm it, we performed a phase II, randomized, open‐label study. Patients with hepatocellular car
Publikováno v:
Cancer Medicine, Vol 10, Iss 4, Pp 1183-1190 (2021)
Cancer Medicine
Cancer Medicine
Background Microsatellite‐stable (MSS) colorectal cancer (CRC) tends to be poorly immunogenic, with limited treatment options. In MSS CRC xenograft models, trifluridine/tipiracil (FTD/TPI) plus programed death 1 inhibitors resulted in synergistic a
Autor:
Sung Shim Cho, Hyunho Kim, Yoon Ho Ko, Byoung Yong Shim, Ho Jung An, Hye Sung Won, Der Sheng Sun, Hyung Soon Park
Publikováno v:
Cancer Medicine, Vol 10, Iss 3, Pp 1057-1065 (2021)
Cancer Medicine
Cancer Medicine
Chemotherapy‐induced nausea and vomiting (CINV) is an unbearable side effect. Identifying high emetic risk patients and providing more active antiemetics strategies are mandatory to improve the tolerability of chemotherapy. In this prospective coho
Autor:
Carine Bellera, Jean-Philippe Metges, Carlos Gomez-Roca, Simon Pernot, François Le Loarer, Celine Auzanneau, Jean-Philippe Guegan, Isabelle Soubeyran, Sophie Cousin, Alban Bessede, Antoine Adenis, Antoine Italiano, Coralie Cantarel, Michèle Kind
Publikováno v:
Clinical Cancer Research. 27:2139-2147
Purpose: Regorafenib is synergistic with immune checkpoint inhibition in colorectal cancer preclinical models. Patients and Methods: This was a single-arm, multicentric phase II trial. Regorafenib was given 3 weeks on/1 week off, 160 mg every day; av
Autor:
Joao Lima, Fabiana Comar, Flávio Mavigner Cárcano, Marco Antonio Oliveira, Arinilda Campos Bragagnoli, Mauricio Wagner Souto Ferraz, Kathia Cristina Abdalla, José B.C. Carvalheira, Lucas Vieira dos Santos, F. A. P. Santos, Raphael L. C. Araujo
Publikováno v:
British Journal of Cancer
Background Patients with refractory colorectal (CRC) cancer have few treatment options. This trial tests the combination of metformin and irinotecan in this setting. Methods A phase 2 single-arm trial was conducted, patients received metformin 2500 m
Autor:
Wulf, Gerald G, Altmann, Bettina, Ziepert, Marita, D'Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M, Van Den Neste, Eric, Lugtenburg, Pieternella J, Doorduijn, Jeanette K, Gelder, Michel van, van Imhoff, Gustaaf W, Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz, ACT-2 study investigators
Publikováno v:
Leukemia, Vol. 35, no.1, p. 143-155 (2021)
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5
Leukemia, 35(1), 143-155. Nature Publishing Group
Leukemia
Leukemia, Springer Nature, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, 143-155. Nature Publishing Group
ISSUE=1;STARTPAGE=143;ENDPAGE=155;ISSN=0887-6924;TITLE=Leukemia
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & for the ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5
Leukemia, 35(1), 143-155. Nature Publishing Group
Leukemia
Leukemia, Springer Nature, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, 35 (1), pp.143-155. ⟨10.1038/s41375-020-0838-5⟩
Leukemia, 143-155. Nature Publishing Group
ISSUE=1;STARTPAGE=143;ENDPAGE=155;ISSN=0887-6924;TITLE=Leukemia
Wulf, G G, Altmann, B, Ziepert, M, D’Amore, F, Held, G, Greil, R, Tournilhac, O, Relander, T, Viardot, A, Wilhelm, M, Wilhelm, C, Pezzutto, A, Zijlstra, J M, Neste, E V D, Lugtenburg, P J, Doorduijn, J K, Gelder, M V, van Imhoff, G W, Zettl, F, Braulke, F, Nickelsen, M, Glass, B, Rosenwald, A, Gaulard, P, Loeffler, M, Pfreundschuh, M, Schmitz, N, Trümper, L & for the ACT-2 study investigators 2021, ' Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma : the DSHNHL2006-1B/ACT-2 trial ', Leukemia, vol. 35, no. 1, pp. 143-155 . https://doi.org/10.1038/s41375-020-0838-5
PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61–80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 36
Autor:
Hiroaki Motoyama, Hikaru Hayashi, Kentaro Fukushima, Yuji Soejima, Shinsuke Sugenoya, Koji Kubota, Kiyotaka Hosoda, Koya Yasukawa, Akira Shimizu, Ryoichiro Kobayashi, Tsuyoshi Notake
Publikováno v:
Oncology. 99:703-712
Introduction: The usefulness of adjuvant chemotherapy in biliary tract cancer (BTC) is poorly reported. This study aimed to evaluate the effectiveness and safety of adjuvant gemcitabine plus S-1 (GS) chemotherapy after curative surgical resection for
Autor:
Chien-Yu Lin, Ching-Hsin Lee, Yung-Chih Chou, Tsung-Ying Ho, Y.Y. Wu, Pei-Rung Chen, Kai-Ping Chang, S.P. Hung, Ngan-Ming Tsang, Wen-Chi Chou, Chia-Hsin Lin, Joseph Tung-Chieh Chang, Chun-Chieh Wang, Bing-Shen Huang, Po-Jui Chen, Kang-Hsing Fan
Publikováno v:
Cancer Medicine, Vol 10, Iss 2, Pp 649-658 (2021)
Cancer Medicine
Cancer Medicine
Objectives To investigate the prognostic value of the preoperative systemic immune‐inflammation index (SII) in patients with oral cavity squamous cell carcinoma (OC‐SCC) treated with curative surgery followed by adjuvant radiotherapy (RT) or chem
Autor:
Young Suk Park, Jeeyun Lee, Hyera Kim, Seonggyu Byeon, Jung Yong Hong, Se Hoon Park, Kee-Taek Jang, Won Ki Kang, Joon Oh Park, Seung Tae Kim, Ho Yeong Lim, Jinchul Kim
Publikováno v:
Oncology. 99:365-372
Background: Biliary tract cancer (BTC) is associated with poor prognosis because of its aggressive and heterogeneous nature. Programmed death ligand 1 (PD-L1) has been considered a novel biomarker for prognosis and response of immune checkpoint inhib